Press Release Sep 20 2022
Filed with NSE · · 7 pages · English
Summary by 6ix AI
This authorization marks NULIBRY as the first approved therapy for this ultra-rare genetic disorder in Europe. The press release highlights the significance of this treatment for patients with a median survival age of about four years. The approval is based on clinical trial data demonstrating the efficacy and safety of NULIBRY compared to historical controls. Zydus Lifesciences expresses its commitment to addressing rare diseases through this milestone achievement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 16 2022
- Press Release Sep 13 2022
- Press Release Sep 12 2022
- Press Release Sep 09 2022
- Press Release Sep 07 2022
Later from Zydus Lifesciences
- Press Release Oct 01 2022
- Press Release Oct 03 2022
- Press Release Oct 04 2022
- Press Release Oct 06 2022
- Zydus Lifesciences: General updates
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences